Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
Cortexin
Cognitive & neuro
Evidence level
Limited evidence
Approval status
Investigational
Mechanism of action
- 1.Proposed neurotrophic and antioxidant activity from the peptide fraction.
- 2.Reported reduction in oxidative stress markers in animal models.
- 3.Reported normalisation of neurotransmitter balance after injury in rodents.
- 4.No single molecular target or active component has been identified.
- 5.Because the content varies by batch, pharmacology is difficult to define.
Studied for
- Cognitive impairment in older adults
- Rehabilitation after stroke
- Childhood attention and language difficulties in Russian trials
- Epilepsy as adjunct therapy
Reported effects
- Small Russian trials report improved cognitive scores
- Effects are not reproduced in independent Western studies
- No reliable data on long-term outcomes
Side effects
- Injection-site irritation
- Allergic reactions
- Agitation or sleep disturbance reported
- No systematic long-term safety data
Research protocol
Research context only - licensed in Russia and a few neighbouring countries, where it is given as 10 mg intramuscularly once daily for ten days. Trials are small, often open-label, and mostly reported in Russian; none has been replicated outside the region.
Research context only
Evidence justification
Small, largely open-label trials in a single region, with no independent replication and no Western regulatory assessment.